Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

Core Insights - MDNA113 is a novel IL-13Rα2 tumor-targeted and "masked" anti-PD-1-IL-2 Superkine designed to deliver anti-PD1 and IL-2 specifically to the tumor microenvironment, addressing high unmet needs in various cancers affecting over 2 million patients annually worldwide [1][3] - The drug is positioned as a first-in-class PD-1-IL-2 bifunctional immunotherapy, aiming to expand the therapeutic window and overcome challenges faced by competing programs [1] - Pre-clinical data demonstrating the selectivity, localization, and potency of MDNA113 will be presented at the AACR Annual Meeting 2026, with an IND submission anticipated in H2 2026 [1][2] Company Overview - Medicenna Therapeutics is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer and autoimmune diseases, including MDNA11, a long-acting IL-2 Superkine [4] - The company utilizes proprietary platforms such as BiSKITs™ and T-MASK™ for the development of its bifunctional immunotherapies [4] - Medicenna's IL-4 Empowered Superkine, bizaxofusp, has been involved in multiple clinical trials and has received FastTrack and Orphan Drug status from the FDA and EMA [4]